Background/Aims: Diabetic nephropathy (DN), a major diabetic microvascular complication, has a long and growing list of biomarkers, including microRNA biomarkers, which have not been consistent across preclinical and clinical studies. This meta-analysis aims to identify significant blood-and urine-incident microRNAs as diagnostic/prognostic biomarker candidates for DN. Methods: PubMed, Web of Science, and Cochrane Library were searched from their earliest records through 12th Dec 2016. Relevant publications for the metaanalysis included (1) human participants; (2) microRNAs in blood and urine; (3) DN studies; and (4) English language. Four reviewers, including two physicians, independently and blindly extracted published data regarding microRNA profiles in blood and/or urine from subjects with diabetic nephropathy. A random-effect model was used to pool the data. Statistical associations between diabetic nephropathy and urinary or blood microRNA expression levels were assessed. Results: Fourteen out of 327 studies (n=2,747 patients) were selected. Blood or urinary microRNA expression data of diabetic nephropathy were pooled for this analysis. The hsa-miR-126 family was significantly (OR: 0.57; 95% CI: 0.44-0.74; p-value < 0.0001) downregulated in blood from patients with diabetic kidney disease, while its urinary level was upregulated (OR: 2931.12; 95% CI: 9.96-862623.21; p-value = 0.0059). The hsa-miR-770 family microRNA were significantly (OR: 10.24; 95% CI: 2.37-44.25; p-value = 0.0018) upregulated in both blood and urine from patients with diabetic nephropathy. Conclusions: Our metaanalysis suggests that hsa-miR-126 and hsa-miR-770 family microRNA may have important diagnostic and pathogenetic implications for DN, which warrants further systematic clinical studies.
Introduction
Diabetes mellitus (DM) has a significant societal and economic burden. This disease may progress into numerous complications, influenced by impaired blood glucose control, disease duration, and genetic factors [1] . In 2015, the International Diabetes Federation estimated that 442 million (uncertainty interval: 340-536 million) people aged 20-79 years suffer from diabetes, with a global economic cost of $673 billion USD. By 2040, diabetes mellitus incidence is predicted to rise to 642 million (uncertainty interval: 521-829 million) [2] . The 2015 mortality from diabetes mellitus was 5.0 million deaths; that number is predicted to increase by 34% in 2030 [3] . These tremendous increases in diabetes mellitus incidence (now affecting 1 of 11 persons) are believed to be due to now-endemic obesity and sedentary lifestyles [1] .
In addition, diabetes is responsible for approximately 50% of cases of incident endstage renal disease (ESRD) [4] . The societal burden of both diabetic nephropathy (DN) and ESRD is enormous, both medically and economically [5, 6] . Among various clinical factors, the major predictor of the development and progression of DN and ESRD is albuminuria [7] . Recently, the list of biomarkers of diabetic nephropathy continues to grow, including not only non-classical protein markers, but also genetic and epigenetic markers [8] [9] [10] . Also, intensive research has sought to identify biomarkers of diabetic kidney disease (DKD) progression. However, the performance of those markers for predicting DN or ESRD progression has been insufficient compared to the "gold standard" clinical measurements, estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) [11] . In particular, circulating blood or urinary microRNAs have been proposed to be novel tools for the diagnosis and prognosis of diabetes [8, 9] . Although various studies have implicated circulating microRNAs as biological markers (and even signal regulators) of DKD, none have been reproducibly shown to associate with diabetes mellitus, nor its renal complications [12] . Additionally, meta-analyses in association with DN and microRNA expression levels have yet to be assessed.
There have been growing lists of microRNA markers for diabetes and its macrovascular and microvascular complications [12] . Furthermore, various clinical studies have shown variable lists of blood or urinary microRNA markers for DN, probably due to small sample sizes, different study designs, the growing list of known microRNAs, and different stages of DN [13] [14] [15] [16] .
Awaiting the larger and more concrete data on microRNA markers for DN via large and well-designed clinical trials, we aimed to examine the relationship between blood or urinary microRNAs and DN by conducting a meta-analysis of pre-existing clinical data on microRNAs and DN.
Materials and Methods

Data Sources and Search Strategy
The databases searched included PubMed, Web of Science, and Cochrane Library, from their earliest records through 12th Dec 2016. For microRNAs associated with DN, we used a combination of keyword terms: diabetes and "miRNA or microRNA" and "microvascular or nephropathy or neuropathy or retinopathy". To secure as many publications as possible, we expanded our search terms to "microvascular" and related terms. We restricted the results to human studies, and references of identified review articles were additionally studied. If necessary, we contacted the corresponding authors to acquire missing information.
Studies were included using the following criteria: (1) those conducted on human subjects relating to the search terms; (2) DN-related studies; (3) microRNA expression results, as exclusively determined by reverse transcription with quantitative PCR (qPCR); and (4) (1) assessed non-relevant outcomes; (2) did not include qPCR-measured microRNA expression; (3) were qualitative in nature, e.g., case reports, comments, review articles, or guidelines; and (4) were based on animal or in vitro (preclinical) models (Fig. 1) .
Study Selection, Data Extraction, and Quality Assessment
Our initial search produced 327 records. As shown in Fig. 1 , application of our inclusion and exclusion criteria resulted in a final total of 14 articles [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] for meta-analysis. From these 14, we extracted (1) microRNA expression levels; (2) DN descriptions; (3) study methods; (4) sample origins; (5) type 1 or 2 diabetes mellitus; (6) microRNA expression measurement; (7) the number of participants; and (8) demographics of the participants, including mean age, gender, diabetes duration, and glycated hemoglobin level ( Table 1 , (for all online suppl. material, see www.karger.com/doi/ 10.1159/000489148) Suppl. Tables S1 and S2). Quality of the 14 individual studies was assessed by following the Cochrane 'Risk of Bias' Tool (see online suppl. material, Suppl. Table S3 ). Discrepancy for selection was resolved by consensus.
Data Synthesis and Analysis
For our analysis, we assigned DN, macroalbuminuria, microalbuminuria, and rapid ESRD to distinct groups of patients with DN complications (henceforth, "case groups"). Healthy controls and patients having normoalbuminuria, no diabetes complications, and no other signs of chronic kidney disease were assigned to distinct groups (henceforth, "control groups"). The 14 studies had different effect size measurements, which were transformed to log odds ratios (natural logarithm of odds ratio) and their standard errors.
Following Cochrane meta-analysis guidelines [30] , we obtained log odds ratio (henceforth, lnOR) and standard error of lnOR (henceforth, SE lnOR ) in a miRNA for each study. We took lnOR and SE lnOR as input in the R meta-analysis package, "meta".
When an odds ratio (OR) and its 95% confidential interval (CI) were given in a study, the following equations were used to convert lnOR and SE lnOR .
(1) (2)
When OR and p-value α were given in a study, lnOR and its SE lnOR were obtained by using the equations. , where the Z value was obtained using the Microsoft Excel™ expression formula, "=ABS(NORMSINV(α/2))". When means and standard deviations for two groups were given in a study, the following steps were used to obtain lnOR and its SE lnOR . A pooled standard deviation (S p ) and Cohen's d (henceforth, d) were calculated to convert to lnOR. 
, where is the number of samples in group i and is a standard deviation of group i. In case SEs or interquartile ranges were given instead of standard deviations, σ i was obtained from the following equations. (6) or (7) , where is the SE of group i, and Q3 i and Q1 i are the third quartile and the first quartile in group i, respectively.
Then, d was obtained by the following equation.
, where is a mean of group i. Finally, lnOR was obtained from the following.
The SE lnOR was converted from variance of d (V d ).
(10)
For sensitivity analysis, we applied a one-study-removed approach to assess the contribution of each study to the pooled effect size. I 2 was considered a criterion of heterogeneity analysis, in random effect models. We also used a trim-and-fill method [31] , to assess the robustness of the effect model, and/or the need to assess publication bias. We also performed the Egger test and examined the resulting funnel plots to identify publication bias [31] . We carried out each of these analyses separately for each microRNA family. All analyses were performed using the "meta" package [32] , version 4.8-1, in R.
Results
Literature Search Results, Study Characteristics, Measurements and Quality
Our search of the PubMed, Web of Science, and Cochrane Library databases led to the retrieval of 327 studies. Of these, 14 case-control studies met our inclusion and exclusion criteria ( Table 1 , Fig. 1 , (see online suppl. material) Suppl. Table S2 ), including a total of 2, 747 subjects (mean sample size, 196; range: 11-591 samples), with a mean age of 46.5 years (range: 30.3-60.9 years) and a mean diabetes duration of 19.1 years (range: 3.5-33.9 years). Details of our inclusion criteria for albuminuria and diabetes mellitus, in the 14 studies, are described (see online suppl. material) in Suppl. 
Park et al.: A Meta-Analysis of MiRNAs in Diabetic Nephropathy
In 11 of the 14 studies, microRNA expression, as detected by qPCR, was calculated using the 2 -∆∆t relative method [33] , using internal controls in each experimental group. Two studies [23, 24] did not use internal controls in each experimental group, while another study [29] did not describe a method for determining microRNA expression from raw qPCR data. Quality assessment of the 14 selected studies was described (see online suppl. material) in Suppl. Table S3 .
Pooled Effects of Diabetic Nephropathy and microRNAs
In urine and blood samples, hsamiR-126 was significantly associated with DN (OR: 8.09; 95% CI: 2.97 to 22.05 with p-value < 0.0001; heterogeneity I 2 = 98% with p-value < 0.01) (see online suppl. material, Suppl. Fig. S1 ), though the directions of these associations were opposite between urine and blood microRNAs ( Fig. 2A and (see online suppl. material) Suppl. Fig. S2A ).
We then performed subgroup analysis of hsa-miR-126 family expression level, according to sample origin. In blood samples, the hsa-miR-126 family was consistently downregulated in case groups compared to control groups (OR 0.57; 95% CI, 0.44 to 0.74 with p-value < 0.0001; heterogeneity I 2 = 72% with p-value < 0.01) (Fig. 2A) . Interestingly, in urine samples, hsa-miR-126 family expression in case groups was upregulated compared to control groups (OR 2931.12; 95% CI, 9.96 to 862623.21 with p-value = 0.0059; heterogeneity I 2 = 97% with p-value < 0.01) (see online suppl. material, Suppl. Fig. S2A ). Another highly significant microRNA we identified was the hsa-miR-770 family. It was upregulated in cases compared to controls (OR 10.24; 95% CI, 2.37 to 44.25 with p-value = 0.0018; heterogeneity I 2 = 64% with p-value = 0.06) (Fig. 2B) .
Sensitivity Analysis and Publication Bias
For our one-study-removed sensitivity analyses, we measured the effects of individual studies on the findings for miR-126 and miR-770 family expression (see previous section). This "sensitivity analysis" (Fig. 3 and (see online suppl. material) Suppl. Fig. S2B ) indicated that individual studies did not change the conclusions.
We also visually inspected publication biases for the DN study models, as shown in (see online suppl. material) Suppl. Fig. S3 . Here, the visual examination of funnel plots showed that all microRNA families' expression levels were not symmetric, implying publication bias. Consequently, we applied a "trim-and-fill" method [31] to estimate the number of potentially missing studies in our meta-analysis. In this method, the random-effects model of the hsa-miR-126 family in blood samples was slightly changed (OR: 0.65; 95% CI: 0.5-0.84 with p-value = 0.001; heterogeneity I 2 = 74% with p-value = 0.0008), with two additional nominal studies. This result indicates that the conclusion of Fig. 2A was robust with regard to publication bias. We also note that due to the small number of studies, the trim-and-fill method was not applied to Fig. 2B and (see online suppl. material) Suppl. Fig. S2A .
Discussion
We meta-analyzed 14 selected clinical studies that had reported an association between circulating or urinary microRNAs and DN [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Our analysis demonstrated significant associations between DN and two microRNAs (hsa-miR-126 and hsa-miR-770 families). In the hsa-miR-126 family, different expression patterns were observed according to the sample origin ( Fig. 2A, and Supplementary Fig. S2A ). Blood hsa-miR-126 expression was lower in DN patients than in control groups (non-DN patients), whereas urinary hsa-miR-126 family expression was higher in case groups compared to control groups. These findings could be explained by positing that a loss of kidney resorption, and subsequent excretion, could deplete the circulating level of has-miR-126. For the hsa-miR-770 family (Fig. 2B) , the same expression patterns were observed between the two sample types, i.e., upregulation in the case groups over the control groups. Although there have been some reports of association between DN and the let-7 family, which are also involved in insulin sensitivity [34] , we could not find an association between the let-7 family and DN (see online suppl. material, Suppl. Fig. S4 ). Additionally, looking into hsa-miR-221, hsa-miR-424, and hsa-miR-192, we did not find any associations with DN (see online suppl. material, Suppl. Fig. S5 ).
In (see online suppl. material) Suppl. Fig. S2A , the 95% CI spanned a wide range, due to usages of different internal controls. In the Liu et al. study [24] , PCR cycles of internal control were arbitrarily set to 50. Other studies, however, used small non-coding RNAs as internal controls for microRNA expression measurements.
Hsa-miR-126 plays an important role in maintaining endothelial cells, in which it enhances vascular endothelial growth factor (VEGF) signaling [35] . Circulating miR-126 level has been negatively correlated with fasting blood glucose and hemoglobin A1c [27] . Interestingly, in contrast to blood miR-126, our meta-analyses showed that urinary miR-126 excretion was significantly increased in patients with DN, although there was a significant heterogeneity. This discrepancy may indicate either a local kidney-specific role or compensatory increases in VEGF and miR-126 in the pathogenesis and/or progression of DN involving microvascular endothelial cells [36, 37] .
Although hsa-miR-770 has often been associated with diabetes and DN [28, [37] [38] [39] , its precise function in diabetes complications remains unclear. Based on its targeting of the nucleotide excision repair enzyme ERCC2 in chemoresistant ovarian cancer [40, 41] and its sequestration by the upregulated lncRNA PCGEM1 in osteoarthritic synoviocytes [42] , one could hypothesize an overall role in apoptosis. Further study is needed to elucidate the molecular mechanisms of miR-770 action in relation with DN.
This meta-analysis has some limitations. Although the number of subjects was more than 2, 700, studies inspecting the same microRNAs were relatively limited, so each aspect of our meta-analysis included a relatively small number of studies. The specific quantification methods of qPCR experiments also differed between studies, and the methods may affect the effect sizes. In fact, microRNA expression quantified in a study by Liu et al. [24] resulted in excessive effect sizes (see online suppl. material, Suppl. Fig. S2A ). Additionally, despite a significant increase in hsa-miR-126 in the urine from DN patients (see online suppl. material, Suppl. Fig. 2A) , the number of studies evaluating urine hsa-miR-126 was small. Another concern on effect measurement in our study could be the inclusion of urinary exosomal miRNAs. Free urinary miRNAs might also originate from the circulation and are confounded by plasma miRNAs which are able to pass the glomerular filtration barrier due to their small molecular weight. Urinary exosomal miRNAs most likely derived from different nephron segments as exosome size is greater than the cut-off size for glomerular filtration even in patients with macroalbuminuria. Therefore, the results should be carefully interpreted. To address these limitations, DN-related analyses of these microRNAs (miR-126 and miR-770) need further investigation, using REMARK guidelines for biomarker translation [43] . Nonetheless, it has now become apparent that small, noncoding RNAs, such as microRNAs, will be reproducible, stable, and accurate biomarkers for numerous human maladies, including life-threatening diabetic nephropathy.
Conclusion
MiRNAs are novel non-invasive markers, indicating promising tools for the mechanistic investigation of diabetic renal pathophysiology (e.g., disease progression) and for potentially enabling us to monitor treatment effects. In near future, there will be more robust and convincing data. One issue is the normalization of data sets. In particular, the selection of an optimal housekeeper (urinary housekeeping miRNA) is a big hurdle, which complicates data comparison of qPCR data. Taken together, this meta-analysis is certainly the first step to get an overview of blood and urinary miRNA expression (miR-126 and miR-770 families) results from studies conducted so far. Nevertheless, miRNA data derived from urinary (exosomal) miRNA expression analyses are still too sparse to make any conclusions.
